Hong Kong Stock Movement | Kexing Pharmaceutical-B (02171.HK) rises over 4% again as its universal CAR-T treatment receives consecutive approvals, and Kailime is included in the million-dollar medical insurance.

Zhitong Finance APP reported that Kecy Pharmaceutical-B (02171.HK) rose over 4% again, reaching an increase of 4.43% as of the time of publication, priced at HKD 15.8, with a trading volume of HKD 26.6335 million.